NCT03246750View on ClinicalTrials.gov

B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

April 10, 2024

Study Completion Date

April 10, 2024

Conditions

Extranodal NK/T-cell Lymphoma

Interventions

DRUG

B-MAD chemotherapy

B-MAD chemotherapy

Trial Locations (1)

10330

King Chulalongkorn Memorial Hospital, Bangkok

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

The Thai Lymphoma Study Group

OTHER